CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 59 enrolled
Drug / intervention
Botulinum Toxins, Type A +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03137407
NCT03137407Phase 2Completed

A Phase 2, Prospective, Randomized, Double-Blinded, Placebo-Controlled Trial of DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis

Revance Therapeutics, Inc.·interventional·Posted May 2, 2017·Updated Sep 18, 2023

In Brief

A Phase 2 clinical trial evaluating Botulinum Toxins, Type A and Placebo for Plantar Fasciitis. Completed, enrolled 59 participants across 5 sites.

Detailed Summary

The specific aim of the study is to compare the safety and efficacy of a single administration of DaxibotulinumtoxinA for Injection versus placebo for managing plantar fasciitis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedMay 2, 2017
Enrollment StartJun 12, 2017
Primary CompletionFeb 20, 2018
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 9.2 years ago

Interventions

Botulinum Toxins, Type Abiological

Intramuscular injection

Placebobiological

Intramuscular injection